Share Price and Basic Stock Data
Last Updated: October 14, 2025, 9:25 am
PEG Ratio | 4.72 |
---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Mankind Pharma Ltd, a prominent player in the pharmaceutical industry, reported a total revenue of ₹8,127 Cr for the fiscal year ending March 2023, marking a steady growth from ₹7,486 Cr in the previous year. The company’s revenue trajectory has been upward, with sales for the trailing twelve months reaching ₹9,498 Cr by March 2025. Quarterly sales figures reveal a consistent performance, with ₹2,260 Cr in September 2023 and ₹2,209 Cr in December 2023, indicating a strong demand for its products. The sales growth reflects Mankind’s strategic positioning in a competitive market, characterized by an operating profit margin (OPM) that stood at 21% for March 2023, showing resilience despite rising costs. The company has effectively managed its operational expenses, which were reported at ₹6,429 Cr for the same period. The continued growth in revenue, alongside controlled expenses, positions Mankind favorably within the pharmaceutical sector, where average OPMs typically range between 15-25%. This robust performance underscores the company’s ability to adapt to market dynamics while maintaining revenue growth.
Profitability and Efficiency Metrics
Mankind Pharma has demonstrated strong profitability metrics, with a net profit of ₹1,945 Cr for the fiscal year ending March 2025, up from ₹1,248 Cr in March 2023. This translates to an earnings per share (EPS) of ₹49.28, reflecting a solid return on equity (ROE) of 13.89%. The quarterly net profit figures indicate a healthy trend, with ₹634 Cr recorded in September 2024 and ₹506 Cr in June 2024. The company’s operating profit margin (OPM) is noteworthy, reaching 27% for March 2025, which is above the typical industry standard. Additionally, the interest coverage ratio (ICR) of 8.28x signifies efficient management of debt obligations, enhancing the company’s financial stability. However, the cash conversion cycle (CCC) has been relatively high, reported at 108 days, which may pose liquidity challenges if not managed effectively. Overall, Mankind’s ability to maintain profitability amidst rising operational costs and competitive pressures highlights its operational efficiency and effective cost management strategies.
Balance Sheet Strength and Financial Ratios
Mankind Pharma’s balance sheet reflects a strong financial position, characterized by total assets amounting to ₹23,828 Cr as of March 2025. The company has reported reserves of ₹14,599 Cr against borrowings of ₹7,254 Cr, resulting in a manageable debt-to-equity ratio of 0.59x. This indicates that Mankind has maintained a conservative approach to leveraging its capital structure, which is critical in the pharmaceutical industry where cash flow stability is paramount. The current ratio of 1.27x suggests adequate short-term liquidity, although the quick ratio stands at 0.89x, indicating potential challenges in meeting immediate liabilities without liquidating inventory. Furthermore, the return on capital employed (ROCE) of 15% for March 2025 demonstrates effective utilization of capital. The company’s financial ratios, including a price-to-book value (P/BV) of 6.98x, suggest that the market has a favorable view of Mankind’s growth potential, although this valuation appears elevated compared to typical sector benchmarks.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Mankind Pharma indicates a strong commitment from its promoters, who hold 72.67% of the total share capital as of June 2025. This level of promoter holding is indicative of aligned interests between management and shareholders, fostering investor confidence. Foreign institutional investors (FIIs) have also increased their stake to 13.07%, up from 4.18% in June 2023, reflecting growing institutional interest in the company. Domestic institutional investors (DIIs) hold 11.50%, suggesting a balanced institutional presence. However, the public shareholding has declined to 2.75%, which may limit liquidity in the stock. The total number of shareholders stood at 179,549, indicating a broad retail investor base. This diversified ownership structure, combined with increasing institutional participation, could enhance stability in the stock price, although the limited public float may introduce volatility during trading periods.
Outlook, Risks, and Final Insight
If Mankind Pharma can sustain its profitability margins and effectively manage its cash conversion cycle, it is well-positioned for continued growth. The company faces potential risks, including rising operational costs and market competition, which could pressure margins. Additionally, fluctuations in regulatory environments and pricing pressures within the pharmaceutical sector may impact future performance. However, Mankind’s strong balance sheet and commitment from promoters provide a solid foundation for navigating these challenges. The ongoing expansion of its product portfolio and strategic focus on high-demand therapeutic areas can further enhance its market position. Overall, Mankind Pharma’s financial health and operational efficiencies, coupled with a favorable sector outlook, position it to capitalize on growth opportunities in the evolving pharmaceutical landscape.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Mankind Pharma Ltd
Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
---|---|---|---|---|---|---|---|---|---|
Mankind Pharma Ltd | 1,00,300 Cr. | 2,430 | 3,055/2,115 | 55.4 | 355 | 0.04 % | 15.0 % | 13.9 % | 1.00 |
Industry Average | 100,300.00 Cr | 2,430.00 | 55.40 | 355.00 | 0.04% | 15.00% | 13.90% | 1.00 |
Quarterly Result
Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sales | 2,061 | 2,258 | 1,936 | 1,872 | 2,092 | 2,260 | 2,209 | 2,007 | 2,413 | 2,530 | 2,414 | 2,127 | 2,541 |
Expenses | 1,641 | 1,735 | 1,563 | 1,491 | 1,594 | 1,662 | 1,636 | 1,482 | 1,837 | 1,778 | 1,668 | 1,650 | 1,868 |
Operating Profit | 420 | 522 | 374 | 381 | 498 | 598 | 573 | 526 | 576 | 752 | 746 | 477 | 673 |
OPM % | 20% | 23% | 19% | 20% | 24% | 26% | 26% | 26% | 24% | 30% | 31% | 22% | 26% |
Other Income | 19 | 69 | 32 | 42 | 87 | 84 | 92 | 109 | 125 | 138 | 70 | 219 | 64 |
Interest | 9 | 8 | 9 | 1 | 2 | 4 | 4 | 4 | 7 | 2 | 200 | 162 | 147 |
Depreciation | 65 | 66 | 71 | 67 | 69 | 77 | 90 | 87 | 91 | 85 | 91 | 105 | 97 |
Profit before tax | 365 | 517 | 326 | 355 | 514 | 601 | 571 | 543 | 603 | 802 | 525 | 429 | 494 |
Tax % | 18% | 19% | 24% | 21% | 20% | 21% | 15% | 14% | 16% | 21% | 22% | 11% | 16% |
Net Profit | 298 | 420 | 249 | 281 | 409 | 473 | 487 | 468 | 506 | 634 | 412 | 382 | 413 |
EPS in Rs | 7.44 | 10.49 | 6.21 | 7.01 | 10.22 | 11.80 | 12.16 | 11.68 | 12.62 | 15.84 | 9.99 | 9.27 | 10.00 |
Last Updated: August 1, 2025, 6:25 am
Below is a detailed analysis of the quarterly data for Mankind Pharma Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 2,541.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,127.00 Cr. (Mar 2025) to 2,541.00 Cr., marking an increase of 414.00 Cr..
- For Expenses, as of Jun 2025, the value is 1,868.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,650.00 Cr. (Mar 2025) to 1,868.00 Cr., marking an increase of 218.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 673.00 Cr.. The value appears strong and on an upward trend. It has increased from 477.00 Cr. (Mar 2025) to 673.00 Cr., marking an increase of 196.00 Cr..
- For OPM %, as of Jun 2025, the value is 26.00%. The value appears strong and on an upward trend. It has increased from 22.00% (Mar 2025) to 26.00%, marking an increase of 4.00%.
- For Other Income, as of Jun 2025, the value is 64.00 Cr.. The value appears to be declining and may need further review. It has decreased from 219.00 Cr. (Mar 2025) to 64.00 Cr., marking a decrease of 155.00 Cr..
- For Interest, as of Jun 2025, the value is 147.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 162.00 Cr. (Mar 2025) to 147.00 Cr., marking a decrease of 15.00 Cr..
- For Depreciation, as of Jun 2025, the value is 97.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 105.00 Cr. (Mar 2025) to 97.00 Cr., marking a decrease of 8.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 494.00 Cr.. The value appears strong and on an upward trend. It has increased from 429.00 Cr. (Mar 2025) to 494.00 Cr., marking an increase of 65.00 Cr..
- For Tax %, as of Jun 2025, the value is 16.00%. The value appears to be increasing, which may not be favorable. It has increased from 11.00% (Mar 2025) to 16.00%, marking an increase of 5.00%.
- For Net Profit, as of Jun 2025, the value is 413.00 Cr.. The value appears strong and on an upward trend. It has increased from 382.00 Cr. (Mar 2025) to 413.00 Cr., marking an increase of 31.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 10.00. The value appears strong and on an upward trend. It has increased from 9.27 (Mar 2025) to 10.00, marking an increase of 0.73.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: July 22, 2025, 2:25 pm
Metric | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
---|---|---|---|---|---|---|---|---|
Sales | 3,918 | 3,829 | 4,794 | 5,523 | 7,486 | 8,127 | 8,629 | 9,498 |
Expenses | 3,141 | 3,124 | 3,550 | 4,151 | 5,644 | 6,429 | 6,358 | 6,930 |
Operating Profit | 778 | 705 | 1,244 | 1,372 | 1,842 | 1,698 | 2,272 | 2,567 |
OPM % | 20% | 18% | 26% | 25% | 25% | 21% | 26% | 27% |
Other Income | 209 | 64 | 94 | 154 | 200 | 163 | 369 | 550 |
Interest | 18 | 40 | 11 | 8 | 48 | 28 | 17 | 372 |
Depreciation | 28 | 38 | 62 | 78 | 123 | 270 | 335 | 378 |
Profit before tax | 941 | 691 | 1,265 | 1,440 | 1,871 | 1,563 | 2,289 | 2,367 |
Tax % | 26% | 26% | 24% | 25% | 26% | 20% | 18% | 18% |
Net Profit | 694 | 514 | 958 | 1,084 | 1,389 | 1,248 | 1,876 | 1,945 |
EPS in Rs | 17.33 | 12.83 | 23.92 | 27.07 | 34.68 | 31.16 | 46.84 | 47.15 |
Dividend Payout % | 0% | 0% | 32% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
Year | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
---|---|---|---|---|---|---|---|
YoY Net Profit Growth (%) | -25.94% | 86.38% | 13.15% | 28.14% | -10.15% | 50.32% | 3.68% |
Change in YoY Net Profit Growth (%) | 0.00% | 112.32% | -73.23% | 14.98% | -38.29% | 60.47% | -46.64% |
Mankind Pharma Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 7 years from 2018-2019 to 2024-2025.
Growth
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | 15% |
3 Years: | 8% |
TTM: | 8% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | 12% |
3 Years: | 8% |
TTM: | -1% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
1 Year: | 4% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | 19% |
3 Years: | 17% |
Last Year: | 14% |
Last Updated: September 5, 2025, 2:40 pm
Balance Sheet
Last Updated: July 25, 2025, 1:43 pm
Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
---|---|---|---|---|---|---|---|---|
Equity Capital | 40 | 40 | 40 | 40 | 40 | 40 | 40 | 41 |
Reserves | 2,957 | 3,025 | 3,611 | 4,694 | 6,500 | 7,744 | 9,663 | 14,599 |
Borrowings | 360 | 190 | 3 | 101 | 688 | 5 | 24 | 7,254 |
Other Liabilities | 652 | 596 | 877 | 1,045 | 1,710 | 1,583 | 1,790 | 1,934 |
Total Liabilities | 4,009 | 3,851 | 4,531 | 5,880 | 8,939 | 9,371 | 11,516 | 23,828 |
Fixed Assets | 534 | 778 | 945 | 987 | 2,927 | 3,142 | 3,552 | 3,471 |
CWIP | 322 | 211 | 148 | 166 | 387 | 495 | 209 | 207 |
Investments | 1,402 | 1,698 | 1,784 | 2,397 | 2,526 | 3,102 | 4,215 | 16,683 |
Other Assets | 1,751 | 1,164 | 1,655 | 2,330 | 3,100 | 2,632 | 3,540 | 3,467 |
Total Assets | 4,009 | 3,851 | 4,531 | 5,880 | 8,939 | 9,371 | 11,516 | 23,828 |
Below is a detailed analysis of the balance sheet data for Mankind Pharma Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 41.00 Cr.. The value appears strong and on an upward trend. It has increased from 40.00 Cr. (Mar 2024) to 41.00 Cr., marking an increase of 1.00 Cr..
- For Reserves, as of Mar 2025, the value is 14,599.00 Cr.. The value appears strong and on an upward trend. It has increased from 9,663.00 Cr. (Mar 2024) to 14,599.00 Cr., marking an increase of 4,936.00 Cr..
- For Borrowings, as of Mar 2025, the value is 7,254.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 24.00 Cr. (Mar 2024) to 7,254.00 Cr., marking an increase of 7,230.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 1,934.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,790.00 Cr. (Mar 2024) to 1,934.00 Cr., marking an increase of 144.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 23,828.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 11,516.00 Cr. (Mar 2024) to 23,828.00 Cr., marking an increase of 12,312.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 3,471.00 Cr.. The value appears to be declining and may need further review. It has decreased from 3,552.00 Cr. (Mar 2024) to 3,471.00 Cr., marking a decrease of 81.00 Cr..
- For CWIP, as of Mar 2025, the value is 207.00 Cr.. The value appears to be declining and may need further review. It has decreased from 209.00 Cr. (Mar 2024) to 207.00 Cr., marking a decrease of 2.00 Cr..
- For Investments, as of Mar 2025, the value is 16,683.00 Cr.. The value appears strong and on an upward trend. It has increased from 4,215.00 Cr. (Mar 2024) to 16,683.00 Cr., marking an increase of 12,468.00 Cr..
- For Other Assets, as of Mar 2025, the value is 3,467.00 Cr.. The value appears to be declining and may need further review. It has decreased from 3,540.00 Cr. (Mar 2024) to 3,467.00 Cr., marking a decrease of 73.00 Cr..
- For Total Assets, as of Mar 2025, the value is 23,828.00 Cr.. The value appears strong and on an upward trend. It has increased from 11,516.00 Cr. (Mar 2024) to 23,828.00 Cr., marking an increase of 12,312.00 Cr..
Notably, the Reserves (14,599.00 Cr.) exceed the Borrowings (7,254.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
---|---|---|---|---|---|---|---|---|
Free Cash Flow | 418.00 | 515.00 | -2.00 | -100.00 | -687.00 | -4.00 | -22.00 | -5.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
---|---|---|---|---|---|---|---|---|
Debtor Days | 23 | 13 | 32 | 24 | 23 | 22 | 33 | 34 |
Inventory Days | 120 | 126 | 124 | 169 | 183 | 132 | 160 | 153 |
Days Payable | 115 | 101 | 113 | 122 | 133 | 103 | 75 | 79 |
Cash Conversion Cycle | 27 | 38 | 43 | 72 | 73 | 52 | 118 | 108 |
Working Capital Days | 95 | 44 | 41 | 42 | 26 | 40 | 55 | -48 |
ROCE % | 22% | 36% | 33% | 30% | 21% | 24% | 15% |
Mutual Fund Holdings
Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
---|---|---|---|---|---|---|
SBI Blue Chip Fund | 2,807,055 | 1.38 | 599.47 | 2,807,055 | 2025-04-22 17:25:13 | 0% |
Axis ELSS Tax Saver Fund | 1,961,633 | 1.23 | 418.93 | 1,961,633 | 2025-04-22 17:25:13 | 0% |
Axis Bluechip Fund | 1,212,614 | 0.79 | 258.97 | 1,212,614 | 2025-04-22 11:41:35 | 0% |
ICICI Prudential Balanced Advantage Fund | 1,154,141 | 0.45 | 246.48 | 1,154,141 | 2025-04-22 17:25:13 | 0% |
SBI Magnum Midcap Fund | 1,123,909 | 1.46 | 240.02 | 1,123,909 | 2025-04-22 17:25:13 | 0% |
HDFC Top 100 Fund - Regular Plan | 1,044,572 | 0.7 | 223.08 | 1,044,572 | 2025-04-22 12:29:18 | 0% |
Nippon India Pharma Fund | 900,794 | 2.7 | 192.37 | 900,794 | 2025-04-22 17:25:13 | 0% |
ICICI Prudential Focused Equity Fund | 845,691 | 2.5 | 180.61 | 845,691 | 2025-04-22 17:25:13 | 0% |
ICICI Prudential Value Discovery Fund | 845,530 | 0.44 | 180.57 | 845,530 | 2025-04-22 17:25:13 | 0% |
ICICI Prudential Equity & Debt Fund | 800,648 | 0.53 | 170.99 | 800,648 | 2025-04-22 17:25:13 | 0% |
Key Financial Ratios
Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
---|---|---|---|---|---|
FaceValue | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
Basic EPS (Rs.) | 49.28 | 47.75 | 32.00 | 35.78 | 31.59 |
Diluted EPS (Rs.) | 49.20 | 47.68 | 32.00 | 35.78 | 31.59 |
Cash EPS (Rs.) | 63.50 | 58.03 | 40.52 | 40.07 | 34.96 |
Book Value[Excl.RevalReserv]/Share (Rs.) | 347.37 | 239.04 | 190.30 | 157.68 | 121.39 |
Book Value[Incl.RevalReserv]/Share (Rs.) | 347.37 | 239.04 | 190.30 | 157.68 | 121.39 |
Revenue From Operations / Share (Rs.) | 295.87 | 257.99 | 218.41 | 194.25 | 155.13 |
PBDIT / Share (Rs.) | 86.15 | 70.29 | 50.66 | 54.55 | 45.41 |
PBIT / Share (Rs.) | 71.10 | 60.35 | 42.52 | 50.39 | 42.44 |
PBT / Share (Rs.) | 60.69 | 59.52 | 41.41 | 48.93 | 41.94 |
Net Profit / Share (Rs.) | 48.45 | 48.09 | 32.38 | 35.91 | 31.99 |
NP After MI And SOA / Share (Rs.) | 48.25 | 47.75 | 32.00 | 35.78 | 31.59 |
PBDIT Margin (%) | 29.11 | 27.24 | 23.19 | 28.08 | 29.27 |
PBIT Margin (%) | 24.03 | 23.39 | 19.46 | 25.94 | 27.35 |
PBT Margin (%) | 20.51 | 23.06 | 18.95 | 25.18 | 27.03 |
Net Profit Margin (%) | 16.37 | 18.64 | 14.82 | 18.48 | 20.61 |
NP After MI And SOA Margin (%) | 16.30 | 18.50 | 14.65 | 18.42 | 20.36 |
Return on Networth / Equity (%) | 13.89 | 20.43 | 17.24 | 23.28 | 26.79 |
Return on Capital Employeed (%) | 13.27 | 24.56 | 21.69 | 30.94 | 33.87 |
Return On Assets (%) | 7.17 | 15.98 | 13.19 | 15.67 | 19.85 |
Long Term Debt / Equity (X) | 0.38 | 0.00 | 0.00 | 0.01 | 0.01 |
Total Debt / Equity (X) | 0.59 | 0.02 | 0.02 | 0.14 | 0.05 |
Asset Turnover Ratio (%) | 0.61 | 0.95 | 0.87 | 0.98 | 1.01 |
Current Ratio (X) | 1.27 | 3.10 | 2.32 | 1.68 | 2.89 |
Quick Ratio (X) | 0.89 | 2.37 | 1.52 | 1.01 | 2.01 |
Inventory Turnover Ratio (X) | 1.11 | 1.21 | 0.50 | 0.64 | 0.57 |
Interest Coverage Ratio (X) | 8.28 | 83.98 | 45.63 | 37.29 | 90.29 |
Interest Coverage Ratio (Post Tax) (X) | 5.64 | 58.45 | 30.17 | 25.54 | 64.60 |
Enterprise Value (Cr.) | 108171.91 | 91239.85 | 0.00 | 0.00 | 0.00 |
EV / Net Operating Revenue (X) | 8.86 | 8.83 | 0.00 | 0.00 | 0.00 |
EV / EBITDA (X) | 30.43 | 32.40 | 0.00 | 0.00 | 0.00 |
MarketCap / Net Operating Revenue (X) | 8.19 | 8.90 | 0.00 | 0.00 | 0.00 |
Price / BV (X) | 6.98 | 9.83 | 0.00 | 0.00 | 0.00 |
Price / Net Operating Revenue (X) | 8.19 | 8.90 | 0.00 | 0.00 | 0.00 |
EarningsYield | 0.01 | 0.02 | 0.00 | 0.00 | 0.00 |
After reviewing the key financial ratios for Mankind Pharma Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 49.28. This value is within the healthy range. It has increased from 47.75 (Mar 24) to 49.28, marking an increase of 1.53.
- For Diluted EPS (Rs.), as of Mar 25, the value is 49.20. This value is within the healthy range. It has increased from 47.68 (Mar 24) to 49.20, marking an increase of 1.52.
- For Cash EPS (Rs.), as of Mar 25, the value is 63.50. This value is within the healthy range. It has increased from 58.03 (Mar 24) to 63.50, marking an increase of 5.47.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 347.37. It has increased from 239.04 (Mar 24) to 347.37, marking an increase of 108.33.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 347.37. It has increased from 239.04 (Mar 24) to 347.37, marking an increase of 108.33.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 295.87. It has increased from 257.99 (Mar 24) to 295.87, marking an increase of 37.88.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 86.15. This value is within the healthy range. It has increased from 70.29 (Mar 24) to 86.15, marking an increase of 15.86.
- For PBIT / Share (Rs.), as of Mar 25, the value is 71.10. This value is within the healthy range. It has increased from 60.35 (Mar 24) to 71.10, marking an increase of 10.75.
- For PBT / Share (Rs.), as of Mar 25, the value is 60.69. This value is within the healthy range. It has increased from 59.52 (Mar 24) to 60.69, marking an increase of 1.17.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 48.45. This value is within the healthy range. It has increased from 48.09 (Mar 24) to 48.45, marking an increase of 0.36.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 48.25. This value is within the healthy range. It has increased from 47.75 (Mar 24) to 48.25, marking an increase of 0.50.
- For PBDIT Margin (%), as of Mar 25, the value is 29.11. This value is within the healthy range. It has increased from 27.24 (Mar 24) to 29.11, marking an increase of 1.87.
- For PBIT Margin (%), as of Mar 25, the value is 24.03. This value exceeds the healthy maximum of 20. It has increased from 23.39 (Mar 24) to 24.03, marking an increase of 0.64.
- For PBT Margin (%), as of Mar 25, the value is 20.51. This value is within the healthy range. It has decreased from 23.06 (Mar 24) to 20.51, marking a decrease of 2.55.
- For Net Profit Margin (%), as of Mar 25, the value is 16.37. This value exceeds the healthy maximum of 10. It has decreased from 18.64 (Mar 24) to 16.37, marking a decrease of 2.27.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 16.30. This value is within the healthy range. It has decreased from 18.50 (Mar 24) to 16.30, marking a decrease of 2.20.
- For Return on Networth / Equity (%), as of Mar 25, the value is 13.89. This value is below the healthy minimum of 15. It has decreased from 20.43 (Mar 24) to 13.89, marking a decrease of 6.54.
- For Return on Capital Employeed (%), as of Mar 25, the value is 13.27. This value is within the healthy range. It has decreased from 24.56 (Mar 24) to 13.27, marking a decrease of 11.29.
- For Return On Assets (%), as of Mar 25, the value is 7.17. This value is within the healthy range. It has decreased from 15.98 (Mar 24) to 7.17, marking a decrease of 8.81.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.38. This value is within the healthy range. It has increased from 0.00 (Mar 24) to 0.38, marking an increase of 0.38.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.59. This value is within the healthy range. It has increased from 0.02 (Mar 24) to 0.59, marking an increase of 0.57.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.61. It has decreased from 0.95 (Mar 24) to 0.61, marking a decrease of 0.34.
- For Current Ratio (X), as of Mar 25, the value is 1.27. This value is below the healthy minimum of 1.5. It has decreased from 3.10 (Mar 24) to 1.27, marking a decrease of 1.83.
- For Quick Ratio (X), as of Mar 25, the value is 0.89. This value is below the healthy minimum of 1. It has decreased from 2.37 (Mar 24) to 0.89, marking a decrease of 1.48.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 1.11. This value is below the healthy minimum of 4. It has decreased from 1.21 (Mar 24) to 1.11, marking a decrease of 0.10.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 8.28. This value is within the healthy range. It has decreased from 83.98 (Mar 24) to 8.28, marking a decrease of 75.70.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 5.64. This value is within the healthy range. It has decreased from 58.45 (Mar 24) to 5.64, marking a decrease of 52.81.
- For Enterprise Value (Cr.), as of Mar 25, the value is 108,171.91. It has increased from 91,239.85 (Mar 24) to 108,171.91, marking an increase of 16,932.06.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 8.86. This value exceeds the healthy maximum of 3. It has increased from 8.83 (Mar 24) to 8.86, marking an increase of 0.03.
- For EV / EBITDA (X), as of Mar 25, the value is 30.43. This value exceeds the healthy maximum of 15. It has decreased from 32.40 (Mar 24) to 30.43, marking a decrease of 1.97.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 8.19. This value exceeds the healthy maximum of 3. It has decreased from 8.90 (Mar 24) to 8.19, marking a decrease of 0.71.
- For Price / BV (X), as of Mar 25, the value is 6.98. This value exceeds the healthy maximum of 3. It has decreased from 9.83 (Mar 24) to 6.98, marking a decrease of 2.85.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 8.19. This value exceeds the healthy maximum of 3. It has decreased from 8.90 (Mar 24) to 8.19, marking a decrease of 0.71.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. It has decreased from 0.02 (Mar 24) to 0.01, marking a decrease of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
Strength | Weakness |
---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Mankind Pharma Ltd:
- Net Profit Margin: 16.37%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 13.27% (Industry Average ROCE: 15%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 13.89% (Industry Average ROE: 13.9%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 5.64
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.89
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 55.4 (Industry average Stock P/E: 55.4)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.59
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 16.37%
About the Company - Qualitative Analysis
INDUSTRY | ADDRESS | CONTACT |
---|---|---|
Pharmaceuticals | 208, Okhla Industrial Estate, Phase-III, New Delhi Delhi 110020 | investors@mankindpharma.com http://www.mankindpharma.com |
Management | |
---|---|
Name | Position Held |
Mr. Ramesh Juneja | Chairman & Wholetime Director |
Mr. Rajeev Juneja | Vice Chairman & Mng.Director |
Ms. Sheetal Arora | Whole Time Director |
Mr. Satish Kumar Sharma | Whole Time Director |
Mr. Vivek Kalra | Independent Director |
Mr. Tilokchand Punamchand Ostwal | Independent Director |
Mr. Bharat Anand | Independent Director |
Ms. Vijaya Sampath | Independent Director |
FAQ
What is the intrinsic value of Mankind Pharma Ltd?
Mankind Pharma Ltd's intrinsic value (as of 14 October 2025) is 2187.85 which is 9.97% lower the current market price of 2,430.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹1,00,300 Cr. market cap, FY2025-2026 high/low of 3,055/2,115, reserves of ₹14,599 Cr, and liabilities of 23,828 Cr.
What is the Market Cap of Mankind Pharma Ltd?
The Market Cap of Mankind Pharma Ltd is 1,00,300 Cr..
What is the current Stock Price of Mankind Pharma Ltd as on 14 October 2025?
The current stock price of Mankind Pharma Ltd as on 14 October 2025 is 2,430.
What is the High / Low of Mankind Pharma Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Mankind Pharma Ltd stocks is 3,055/2,115.
What is the Stock P/E of Mankind Pharma Ltd?
The Stock P/E of Mankind Pharma Ltd is 55.4.
What is the Book Value of Mankind Pharma Ltd?
The Book Value of Mankind Pharma Ltd is 355.
What is the Dividend Yield of Mankind Pharma Ltd?
The Dividend Yield of Mankind Pharma Ltd is 0.04 %.
What is the ROCE of Mankind Pharma Ltd?
The ROCE of Mankind Pharma Ltd is 15.0 %.
What is the ROE of Mankind Pharma Ltd?
The ROE of Mankind Pharma Ltd is 13.9 %.
What is the Face Value of Mankind Pharma Ltd?
The Face Value of Mankind Pharma Ltd is 1.00.